Development and Commercialization Efforts. Corregidor shall, itself or with or through its Affiliates and Collaboration Partners, use Commercially Reasonable Efforts to Develop and Commercialize Licensed Products.
Development and Commercialization Efforts. LICENSEE (i) shall use commercially reasonable efforts to diligently conduct such preclinical and clinical trials that are necessary or desirable to obtain all regulatory approvals to develop and commercialize such PRODUCTS, (ii) shall diligently develop and obtain necessary approval to market such PRODUCTS (including, as the case may be, pricing approval), and (iii) shall commence marketing and market such PRODUCTS in each country in which LICENSEE has received all applicable regulatory approvals therefor. LICENSEE shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of such PRODUCTS, and shall cause its Affiliates and subcontractors to do the same. LICENSEE shall be solely responsible for funding all costs of the development and commercialization of each such PRODUCTS.
Development and Commercialization Efforts. PMC shall develop, commercialize and market Products using efforts at least comparable to the resources PMC invests in its internally developed priority projects. Without limiting the foregoing, PMC (i) shall conduct such preclinical and clinical trials as are necessary or desirable to obtain all regulatory approvals to develop and commercialize such Products as and where PMC determines are commercially feasible, (ii) shall diligently develop and obtain necessary approval to market such Products (including, as the case may be, pricing approval), and (iii) shall commence marketing and market such Product in each country in which PMC has received all applicable regulatory approvals therefor. PMC shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of such Products, and shall cause its Affiliates and subcontractors to do the same. PMC shall be solely responsible for funding all costs of the development and commercialization of each such Product. PMC shall keep CORIXA informed in a timely manner as to the progress of the development of Products.
Development and Commercialization Efforts. LICENSEE shall comply with all applicable good laboratory, clinical and manufacturing practices in the development and commercialization of PRODUCTS, and shall cause its Affiliates and subcontractors to do the same. LICENSEE shall be solely responsible for funding all costs incurred by LICENSEE for the development and commercialization of each PRODUCT.
Development and Commercialization Efforts. From and after the Closing Date, the Purchaser shall use its commercially reasonable efforts to develop and commercialize at least one drug candidate resulting from the 784 Patent Rights that meets the Purchaser's criteria for clinical development. In the event the Board of Directors of the Purchaser shall determine to abandon its development and commercialization efforts with respect to the 784 Patent Rights, the Board of Directors of the Purchaser shall notify the Seller in writing within 10 days of the Board's determination (the "NOTICE"), and the Seller shall have the right, in its sole discretion, to repurchase the 784 Patent Rights from the Purchaser at a price to be mutually agreed to by the parties in good faith; PROVIDED, that such price shall not exceed the fair market value of that portion of the consideration received by the Seller for such patent rights pursuant to this Agreement plus the aggregate amount spent by the Purchaser to maintain the 784 Patent Rights from the Closing Date. In order to exercise its right to repurchase the 784 Patent Rights pursuant to this Section 4.1, the Seller must notify the Purchaser, in writing, of its intent to repurchase within 30 days after receipt of the Notice by the Seller. Any sale or license of the 784
Development and Commercialization Efforts. From and after the date hereof, Callisto shall use its commercially reasonable efforts to develop and commercialize at least one drug candidate resulting from the 412 Patent Rights that meet Callisto's criteria for clinical development. Callisto shall have the sole ownership in and to any and all intellectual property rights resulting from Callisto's development efforts (the "Developments"). In the event that HPI exercises its right to terminate this Agreement pursuant to Section 6 by reason of Callisto's material breach of this Section 4.4 or as a result of a determination by Callisto's Board of Directors to abandon its development and commercialization efforts with respect to the 412 Patent Rights, Callisto agrees to grant HPI, on commercially reasonable terms, a non-exclusive license to use any of the Developments that, in the mutual determination of Callisto and HPI, are necessary to enable HPI to develop and commercialize any drug candidates resulting from the 412 Patent Rights.
Development and Commercialization Efforts. As set forth therein, Opus will, and will cause its Affiliates and Product Licensees to meet the level of diligence required with respect to the Development and Commercialization of IC-200 Product as required pursuant to the IC-200 License Agreement. Opus will deliver to Iveric all reports owed to the Institution Licensors under the Assigned License Agreements. Section 5.1.2 sets forth Xxxxxx’s sole remedy for breach of this Section 5.1.1.
Development and Commercialization Efforts. LICENSEE shall comply with all applicable and reasonable industry best-practices in the development and commercialization of the products and/or services using the Licensed Technology, and shall cause its affiliates and subcontractors to do the same. LICENSEE shall be solely responsible for all development and commercialization costs. WINTR.4000.01 Page 5 of 25 ___________ ___________ LICENSOR LICENSEE Intellectual Property License And Consulting Agreement
Development and Commercialization Efforts. Novartis shall use commercially reasonable efforts, similar to those used by Novartis or its Affiliates in the research, development and commercialization of other products of Novartis or its Affiliates that are of similar commercial potential and at a similar stage of development, to develop and commercialize Products hereunder.
Development and Commercialization Efforts. 3.1.1 deCODE shall exercise diligent efforts at its own cost to have the QT PROLONGATION EVALUATION completed as soon as possible after receipt of COMPOUND and BAYER KNOW HOW according to the timeline and study plan contained in Schedule D.
